annual cash & cash equivalents:
$28.36M-$6.46M(-18.55%)Summary
- As of today (July 3, 2025), CLDX annual cash & cash equivalents is $28.36 million, with the most recent change of -$6.46 million (-18.55%) on December 31, 2024.
- During the last 3 years, CLDX annual cash & cash equivalents has fallen by -$10.79 million (-27.56%).
- CLDX annual cash & cash equivalents is now -83.26% below its all-time high of $169.40 million, reached on December 31, 2013.
Performance
CLDX Cash and cash equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
quarterly cash & cash equivalents:
$17.14M-$11.22M(-39.57%)Summary
- As of today (July 3, 2025), CLDX quarterly cash & cash equivalents is $17.14 million, with the most recent change of -$11.22 million (-39.57%) on March 31, 2025.
- Over the past year, CLDX quarterly cash & cash equivalents has dropped by -$97.94 million (-85.11%).
- CLDX quarterly cash & cash equivalents is now -89.88% below its all-time high of $169.40 million, reached on December 31, 2013.
Performance
CLDX quarterly cash & cash equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
Cash and cash equivalents Formula
Cash & Cash Equivalents = Cash + Short-Term Investments
CLDX Cash and cash equivalents Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | -18.6% | -85.1% |
| 3 y3 years | -27.6% | -32.3% |
| 5 y5 years | +152.5% | -24.6% |
CLDX Cash and cash equivalents Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | -27.6% | at low | -85.1% | at low |
| 5 y | 5-year | -35.3% | +152.5% | -85.1% | at low |
| alltime | all time | -83.3% | +1081.5% | -89.9% | +614.0% |
CLDX Cash and cash equivalents History
| Date | Annual | Quarterly |
|---|---|---|
| Mar 2025 | - | $17.14M(-39.6%) |
| Dec 2024 | $28.36M(-18.6%) | $28.36M(-22.1%) |
| Sep 2024 | - | $36.40M(-14.8%) |
| Jun 2024 | - | $42.74M(-62.9%) |
| Mar 2024 | - | $115.08M(+230.5%) |
| Dec 2023 | $34.81M(+18.3%) | $34.81M(+64.7%) |
| Sep 2023 | - | $21.13M(-25.1%) |
| Jun 2023 | - | $28.22M(-47.9%) |
| Mar 2023 | - | $54.12M(+83.9%) |
| Dec 2022 | $29.43M(-24.8%) | $29.43M(+58.4%) |
| Sep 2022 | - | $18.58M(-34.6%) |
| Jun 2022 | - | $28.40M(+12.3%) |
| Mar 2022 | - | $25.29M(-35.4%) |
| Dec 2021 | $39.14M(-10.7%) | $39.14M(-45.8%) |
| Sep 2021 | - | $72.18M(+66.1%) |
| Jun 2021 | - | $43.45M(-37.3%) |
| Mar 2021 | - | $69.31M(+58.1%) |
| Dec 2020 | $43.84M(+290.3%) | $43.84M(+141.5%) |
| Sep 2020 | - | $18.15M(-73.3%) |
| Jun 2020 | - | $68.03M(+199.4%) |
| Mar 2020 | - | $22.72M(+102.3%) |
| Dec 2019 | $11.23M(-53.8%) | $11.23M(-32.3%) |
| Sep 2019 | - | $16.59M(-16.0%) |
| Jun 2019 | - | $19.74M(-37.4%) |
| Mar 2019 | - | $31.53M(+29.7%) |
| Dec 2018 | $24.31M(-39.7%) | $24.31M(-25.9%) |
| Sep 2018 | - | $32.82M(-25.2%) |
| Jun 2018 | - | $43.89M(+10.2%) |
| Mar 2018 | - | $39.82M(-1.2%) |
| Dec 2017 | $40.29M(-5.1%) | $40.29M(-26.4%) |
| Sep 2017 | - | $54.73M(-17.3%) |
| Jun 2017 | - | $66.16M(+55.7%) |
| Mar 2017 | - | $42.50M(+0.1%) |
| Dec 2016 | $42.46M(-41.1%) | $42.46M(+33.8%) |
| Sep 2016 | - | $31.74M(-2.3%) |
| Jun 2016 | - | $32.48M(-48.5%) |
| Mar 2016 | - | $63.02M(-12.6%) |
| Dec 2015 | $72.11M(+157.3%) | $72.11M(+8.0%) |
| Sep 2015 | - | $66.79M(-18.1%) |
| Jun 2015 | - | $81.58M(-33.2%) |
| Mar 2015 | - | $122.17M(+336.0%) |
| Dec 2014 | $28.02M(-83.5%) | $28.02M(-13.9%) |
| Sep 2014 | - | $32.52M(-20.3%) |
| Jun 2014 | - | $40.80M(-28.3%) |
| Mar 2014 | - | $56.90M(-66.4%) |
| Dec 2013 | $169.40M(+580.4%) | $169.40M(+1058.2%) |
| Sep 2013 | - | $14.63M(-43.5%) |
| Jun 2013 | - | $25.90M(-65.8%) |
| Mar 2013 | - | $75.63M(+203.8%) |
| Dec 2012 | $24.90M(+109.2%) | $24.90M(+7.4%) |
| Sep 2012 | - | $23.19M(+24.9%) |
| Jun 2012 | - | $18.56M(-18.4%) |
| Mar 2012 | - | $22.75M(+91.2%) |
| Dec 2011 | $11.90M(-44.1%) | $11.90M(-9.1%) |
| Sep 2011 | - | $13.10M(+20.9%) |
| Jun 2011 | - | $10.83M(+6.8%) |
| Mar 2011 | - | $10.14M(-52.4%) |
| Dec 2010 | $21.29M(-62.7%) | $21.29M(+116.6%) |
| Sep 2010 | - | $9.83M(-35.2%) |
| Jun 2010 | - | $15.16M(-64.5%) |
| Mar 2010 | - | $42.67M(-25.1%) |
| Dec 2009 | $57.00M(+28.8%) | $57.00M(+119.4%) |
| Sep 2009 | - | $25.98M(-17.9%) |
| Jun 2009 | - | $31.63M(-19.6%) |
| Mar 2009 | - | $39.36M(-11.1%) |
| Dec 2008 | $44.26M(+801.5%) | $44.26M(+3.7%) |
| Sep 2008 | - | $42.70M(-18.5%) |
| Jun 2008 | - | $52.38M(+358.7%) |
| Mar 2008 | - | $11.42M(+132.6%) |
| Dec 2007 | $4.91M(-88.0%) | $4.91M(-75.9%) |
| Sep 2007 | - | $20.34M(-21.5%) |
| Jun 2007 | - | $25.91M(-20.5%) |
| Mar 2007 | - | $32.57M(-20.4%) |
| Date | Annual | Quarterly |
|---|---|---|
| Dec 2006 | $40.91M(+74.7%) | $40.91M(-12.4%) |
| Sep 2006 | - | $46.68M(-12.7%) |
| Jun 2006 | - | $53.47M(-10.5%) |
| Mar 2006 | - | $59.76M(+155.2%) |
| Dec 2005 | $23.42M(-26.2%) | $23.42M(+5.5%) |
| Sep 2005 | - | $22.20M(-17.9%) |
| Jun 2005 | - | $27.03M(-1.0%) |
| Mar 2005 | - | $27.31M(-14.0%) |
| Dec 2004 | $31.74M(+56.7%) | $31.74M(-9.9%) |
| Sep 2004 | - | $35.23M(-10.5%) |
| Jun 2004 | - | $39.37M(-4.4%) |
| Mar 2004 | - | $41.16M(+103.3%) |
| Dec 2003 | $20.25M(-19.2%) | $20.25M(-13.8%) |
| Sep 2003 | - | $23.50M(+38.4%) |
| Jun 2003 | - | $16.98M(-14.0%) |
| Mar 2003 | - | $19.75M(-21.2%) |
| Dec 2002 | $25.07M(-41.2%) | $25.07M(-4.7%) |
| Sep 2002 | - | $26.31M(-16.9%) |
| Jun 2002 | - | $31.67M(-14.5%) |
| Mar 2002 | - | $37.05M(-13.2%) |
| Dec 2001 | $42.67M(-15.0%) | $42.67M(+22.8%) |
| Sep 2001 | - | $34.74M(-14.7%) |
| Jun 2001 | - | $40.71M(-9.8%) |
| Mar 2001 | - | $45.11M(-10.1%) |
| Dec 2000 | $50.18M(+268.4%) | $50.18M(+3.4%) |
| Sep 2000 | - | $48.51M(+202.1%) |
| Jun 2000 | - | $16.06M(-14.4%) |
| Mar 2000 | - | $18.76M(+37.8%) |
| Dec 1999 | $13.62M(+53.0%) | $13.62M(-13.8%) |
| Sep 1999 | - | $15.80M(+88.1%) |
| Jun 1999 | - | $8.40M(-23.6%) |
| Mar 1999 | - | $11.00M(+23.6%) |
| Dec 1998 | $8.90M(+39.1%) | $8.90M(+23.6%) |
| Sep 1998 | - | $7.20M(+38.5%) |
| Jun 1998 | - | $5.20M(-36.6%) |
| Mar 1998 | - | $8.20M(+28.1%) |
| Dec 1997 | $6.40M(-49.2%) | $6.40M(-24.7%) |
| Sep 1997 | - | $8.50M(-20.6%) |
| Jun 1997 | - | $10.70M(-12.3%) |
| Mar 1997 | - | $12.20M(-3.2%) |
| Dec 1996 | $12.60M(+2.4%) | $12.60M(-12.5%) |
| Sep 1996 | - | $14.40M(+114.9%) |
| Jun 1996 | - | $6.70M(-28.7%) |
| Mar 1996 | - | $9.40M(-23.6%) |
| Dec 1995 | $12.30M(+61.8%) | $12.30M(+98.4%) |
| Sep 1995 | - | $6.20M(-41.0%) |
| Jun 1995 | - | $10.50M(-18.6%) |
| Mar 1995 | - | $12.90M(+69.7%) |
| Dec 1994 | $7.60M(-73.1%) | $7.60M(-59.4%) |
| Sep 1994 | - | $18.70M(-10.1%) |
| Jun 1994 | - | $20.80M(-14.8%) |
| Mar 1994 | - | $24.40M(-13.8%) |
| Dec 1993 | $28.30M(+757.6%) | $28.30M(+133.9%) |
| Sep 1993 | - | $12.10M(-11.0%) |
| Jun 1993 | - | $13.60M(-12.8%) |
| Mar 1993 | - | $15.60M(-17.9%) |
| Dec 1992 | $3.30M(-85.1%) | - |
| Oct 1992 | - | $19.00M(-8.2%) |
| Jul 1992 | - | $20.70M(-6.3%) |
| Apr 1992 | - | $22.10M(-4.3%) |
| Apr 1992 | $22.10M(+154.0%) | - |
| Jan 1992 | - | $23.10M(-3.8%) |
| Oct 1991 | - | $24.00M(-5.9%) |
| Jul 1991 | - | $25.50M(+193.1%) |
| Apr 1991 | $8.70M(-23.0%) | $8.70M(+7.4%) |
| Jan 1991 | - | $8.10M(-12.9%) |
| Oct 1990 | - | $9.30M(-15.5%) |
| Jul 1990 | - | $11.00M(-2.7%) |
| Apr 1990 | $11.30M(+17.7%) | $11.30M(+56.9%) |
| Jan 1990 | - | $7.20M(-25.0%) |
| Apr 1989 | $9.60M(-11.1%) | $9.60M(-11.1%) |
| Apr 1988 | $10.80M(-20.0%) | $10.80M(-20.0%) |
| Apr 1987 | $13.50M(+462.5%) | $13.50M(+462.5%) |
| Apr 1986 | $2.40M | $2.40M |
FAQ
- What is Celldex Therapeutics annual cash & cash equivalents?
- What is the all time high annual cash & cash equivalents for Celldex Therapeutics?
- What is Celldex Therapeutics annual cash & cash equivalents year-on-year change?
- What is Celldex Therapeutics quarterly cash & cash equivalents?
- What is the all time high quarterly cash & cash equivalents for Celldex Therapeutics?
- What is Celldex Therapeutics quarterly cash & cash equivalents year-on-year change?
What is Celldex Therapeutics annual cash & cash equivalents?
The current annual cash & cash equivalents of CLDX is $28.36M
What is the all time high annual cash & cash equivalents for Celldex Therapeutics?
Celldex Therapeutics all-time high annual cash & cash equivalents is $169.40M
What is Celldex Therapeutics annual cash & cash equivalents year-on-year change?
Over the past year, CLDX annual cash & cash equivalents has changed by -$6.46M (-18.55%)
What is Celldex Therapeutics quarterly cash & cash equivalents?
The current quarterly cash & cash equivalents of CLDX is $17.14M
What is the all time high quarterly cash & cash equivalents for Celldex Therapeutics?
Celldex Therapeutics all-time high quarterly cash & cash equivalents is $169.40M
What is Celldex Therapeutics quarterly cash & cash equivalents year-on-year change?
Over the past year, CLDX quarterly cash & cash equivalents has changed by -$97.94M (-85.11%)